Usage Patterns of Stop Smoking Medications in Australia, Canada, the United Kingdom, and the United States

Varenicline is a new prescription stop smoking medication (SSM) that has been available in the United States since August 1, 2006, in the United Kingdom and other European Union countries since December 5, 2006, in Canada since April 12, 2007, and in Australia since January 1, 2008. There are few population-based studies that have examined use rates of varenicline and other stop smoking medications. We report data from the ITC Four Country survey conducted with smokers in the US, UK, Canada, and Australia who reported an attempt to quit smoking in past year in the 2006 survey (n = 4,022 participants), 2007 (n = 3,790 participants), and 2008 surveys (n = 2,735 participants) Respondents reported use of various stop smoking medications to quit smoking at each survey wave, along with demographic and smoker characteristics. The self-reported use of any stop smoking medication has increased significantly over the 3 year period in all 4 countries, with the sharpest increase occurring in the United States. Varenicline has become the second most used stop smoking medication, behind NRT, in all 4 countries since being introduced. Between 2006 and 2008, varenicline use rates increased from 0.4% to 21.7% in the US, 0.0% to 14.8% in Canada, 0.0% to 14.5% in Australia, and 0.0% to 4.4% in the UK. In contrast, use of NRT and bupropion remained constant in each country. Males and non-whites were significantly less likely to report using any SSM, while more educated smokers were significantly more likely to use any SSM, including varenicline. Our findings suggest that the introduction of varenicline led to an increase in the number of smokers who used evidence-based treatment during their quit attempts, rather than simply gaining market share at the expense of other medications. From a public health perspective, messages regarding increased success rates among medication users and the relative safety of stop smoking medications should be disseminated widely so as to reach all smokers of all socioeconomic classifications equally

Bupropion · Environmental health · European union · Medical prescription · Population · Public health · Smoking cessation · Smoking prevalence · Tobacco control · Varenicline · Behavioral Health and Interventions · Demography · Global Public Health Policies and Epidemiology · Medicine · Smoking Behavior and Cessation

• Quitting smoking before and after varenicline

  Shu‐Hong Zhu, Sharon E Cummins et al.•Tobacco Control•2015

  Incluir item

• Shape of the relapse curve and long‐term abstinence among untreated smokers

  Open Access•John R Hughes, Josue Keely et al.•Addiction•2004

  Incluir item

• Methods of the International Tobacco Control (ITC) Four Country Survey

  M E Thompson, G T Fong et al.•Tobacco Control•2006

  Incluir item

• Impact of UK policy initiatives on use of medicines to aid smoking cessation

  Robert West, M E DiMarino et al.•Tobacco Control•2005

  Incluir item

• Public health benefit of over-the-counter nicotine medications

  Saul Shiffman, Joe Gitchell et al.•Tobacco Control•1997

  Incluir item

• Use of Pharmacy Data to Evaluate Smoking Regulations’ Impact on Sales of Nicotine Replacement Therapies in New York City

  Kristina B Metzger, Farzad Mostashari et al.•American Journal of Public Health•2005

  Incluir item